Synapse - Mark Kris

Search Within

Mark Kris

Results (63)

Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events

Meeting Abstract

Basch, E. M.; McDonough, T.; Iasonos, A.; Siegel, E.; Culkin, A.; Kris, M.; Scher, H. I.; Schrag, D.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

Pharmacokinetics and toxicity of weekly docetaxel in older patients

Journal Article

Hurria, A.; Fleming, M. T.; Baker, S. D.; Kelly, Wm K.; Cutchall, K.; Panageas, K.; Caravelli, J.; Yeung, H.; Kris, M. G.; Gomez, J.; more...
Clinical Cancer Research (2006)

Fulltext@MSK | Save

Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study

Journal Article

Basch, E.; Iasonos, A.; McDonough, T.; Barz, A.; Culkin, A.; Kris, M. G.; Scher, H. I.; Schrag, D.
Lancet Oncology (2006)

Fulltext@MSK | Save

A phase I dose escalation trial of pulsatile high dose gefitinib and docetaxel in patients with an advanced solid tumor

Meeting Abstract

Fury, M. G.; Kris, M.; Solit, D.; Pfister, D. G.; Azzoli, C. G.; Henry, R.; Su, Y. B.; Rizvi, N.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel

Journal Article

Solit, D. B.; She, Y.; Lobo, J.; Kris, M. G.; Scher, H. I.; Rosen, N.; Sirotnak, F. M.
Clinical Cancer Research (2005)

Fulltext@MSK | Save

Pulsatile administration of the EGF receptor inhibitor Iressa (ZD1839) is significantly more effective than continuous dosing for sensitizing tumors to taxol

Meeting Abstract

Solit, D. B.; She, Y.; Moasser, M. M.; Hudis, C. A.; Kris, M. G.; Scher, H. I.; Rosen, N.; Sirotnak, F. M.
Proceedings of the American Association for Cancer Research Annual Meeting (2003)

Fulltext@MSK | Save

Pulsatile administration of the EGF receptor inhibitor gefitinib (Iressa, ZD 1839) is significantly more effective than continuous dosing for sensitizing tumors to Taxol

Meeting Abstract

Solit, D. B.; She, Y.; Moasser, M.; Hudis, C.; Kris, M.; Scher, H.; Rosen, N.; Sirotnak, F. M.
Clinical Cancer Research (2003)

Fulltext@MSK | Save

Low-level co-expression of multiple MRP genes including the newly described MRP-7 limits intrinsic sensitivity of drug naive human tumors to a folate analogue, cisplatin and paclitaxel

Meeting Abstract

Wendel, H. G.; Scher, H. I.; Miller, V. A.; Kris, M. G.; Sirotnak, F. M.
Clinical Cancer Research (2001)

Fulltext@MSK | Save

Potentiation of cytotoxic agents against human tumors in mice by ZD1839 (IressaTM), an inhibitor of EGFR tyrosine kinase, does not require high levels of expression of EGFR

Meeting Abstract

Sirotnak, F. M.; Zakowski, M. F.; Miller, V. A.; Scher, H. I.; Kris, M. G.
Proceedings of the American Association for Cancer Research Annual Meeting (2000)

Fulltext@MSK | Save

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase

Journal Article

Sirotnak, F. M.; Zakowski, M. F.; Miller, V. A.; Scher, H. I.; Kris, M. G.
Clinical Cancer Research (2000)

Fulltext@MSK | Save